KR940006602A - 면역글로불린 이소타입에 대한 재조형 모노클로날 항체 - Google Patents
면역글로불린 이소타입에 대한 재조형 모노클로날 항체 Download PDFInfo
- Publication number
- KR940006602A KR940006602A KR1019930019631A KR930019631A KR940006602A KR 940006602 A KR940006602 A KR 940006602A KR 1019930019631 A KR1019930019631 A KR 1019930019631A KR 930019631 A KR930019631 A KR 930019631A KR 940006602 A KR940006602 A KR 940006602A
- Authority
- KR
- South Korea
- Prior art keywords
- amino acid
- ser
- acid sequence
- tyr
- phe
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title abstract 2
- 102000018358 immunoglobulin Human genes 0.000 title abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 27
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 6
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 235000002918 Fraxinus excelsior Nutrition 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- LGEYOIQBBIPHQN-UWJYBYFXSA-N Tyr-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 LGEYOIQBBIPHQN-UWJYBYFXSA-N 0.000 claims 1
- 239000002956 ash Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6873—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an immunoglobulin; the antibody being an anti-idiotypic antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
- C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
본 발명은 이소타입 면역글로블린 E(IgE)의 결정소에 대한 재조형 사람 모노클로날 항체, 이 항체의 직접 등가물 및 유도체에 관한 것이다. 본 발명의 분자는 알레르기 진단, 예방 및 치료에 유용한다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 사람 k경쇄불변 영역에 융합된 C21-L1 및 사람 r1증쇄불변 영역에 융합된 C21-H1제조에 사용되는 HCMV-1포유동물 발현벡터를 나타낸다.
Claims (21)
- 서열중에 과가변성 영역은 Met-Tyr-Trp-Leu-Glu의 아미노산 서열을 갖는 CDR1, Glu-Ile-Ser-Pro-Gly-Thr-Phe-Thr-Asn-Tyr-Asn-Glu-Lys-Ala의 아미노산 서열을 갖는 CDR2 및 Phe-Ser-His-Phe-Ser-Gly-Ser-Asn-Tyr-Phe-Asp-Tyr-Phe-Asp-Tyr의 아미노산 서열을 갖는 CDR3을 차례로 포함하는, 쥐와 CDR-공여항체 TES-C21과 적어도 거의 동등한 항원결합 친화도를 갖는 항원 결합 부위를 갖는 IgE에 특이적인 재조형 사람 모노클로날 항체, 이 재조형 항체의 직접 등가물 또는 유도체.
- 제1항에 있어서, a)과가변성 영역은 Met-Tyr-Trp-Leu-Glu의 아미노산 서열을 갖는 CDR1, Glu-Ile-Ser-Pro-Gly-Thr-Phe-Thr-Thr-Asn-Tyr-Asn-Glu-Lys-Phe-Lys-Ala의 아미노산 서열을 갖는 CDR2 및 Phe-Ser-His-Phe-Ser-Gly-Ser-Asn-Tyr-Asp-Tyr-Phe-Asp-Tyr의 아미노산 서열을 갖는 CDR3을 차례로 포함하는 제1영역 및 b) 서열중에 과가변성 영역인 Arg-Ala-Ser-Gln-Ser-Ile-Gly-Thr-Asn-Ile-His의 아미노산 서열을 갖는 CDR1, Tyr-Ala-Ser-Glu-Ser-Ile-Ser의 아미노산 서열을 갖는 CDR2및 Gln-Gln-Ser-Asp-Ser-Trp-Pro-Thr-Thr의 아미노산 서열을 갖는 CDR3을 포함하는 제2영역을 포함하는, 쥐와 CDR-공여 항체 TES-C21과 적어도 거의 동등한 항원 결합 친화도를 갖는 하나의 항원 결합 부위를 함유하는 재조형 사람 항체, 이 재조형 사람 항체의 직접 등가물 또는 유도체.
- 제2항에 있어서, a)서열중에, 과가변성 영역인 Met-Tyr-Trp-Leu-Glu의 아미노산 서열을 갖는 CDR1H, Glu-Ile-Ser-Pro-Gly-Thr-Phe-Thr-Thr-Asn-Tyr-Asn-Glu-Lys-Phe-Lys-Ala의 아미노산 서열을 갖는 CDR2H및 Phe-Ser-His-Phe-Ser-Gly-Ser-Asn-Tyr-Asp-Tyr-Phe-Asp-Tyr-Phe-Asp-Tyr의 아미노산 성열을 갖는 CDR3H및 사람 중쇄의 불변부분 또는 이의 단편을 포함하여, 가변성 영역을 함유하는 하나의 면역글로블린 중쇄 또는 이의 단편 및 b)서열중에, 과가변성 영역인 Arg-Ala-Ser-Gln-Ser-Ile-Gly-Thr-Asn-Ile-His의 아미노산 서열을 갖는 CDR1L, Tyr-Ala-Ser-Glu-Ser-Ile-Ser의 아미노산 서열을 갖는 CDR2L및 Gln-Gln-Ser-Asp-Ser-Trp-Pro-Thr-Thr의 아미노산 서열을 갖는 CDR3L및 사람 경쇄의 불변부분 또는 이의 단편을 포함하여, 경쇄 가변성 영역을 함유하는 하나의 면역글로블린 경쇄 또는 이의 단편을 포함하는 재조형 사람 항체, 이 재조형 항체의 직접 등가물 또는 유도체.
- 제2항에 있어서, a)아미노산 위치 1에서 시작하고 아미노산 위치 123에서 종료되는 SEQ ID NO. 11에 나타낸 것과 실질적으로 동일한 아미노산 서열을 갖는 가변성영역 및 사람 중쇄의 불변부분을 포함하는 하나의 중쇄 및 b)아미노산 위치 1에서 시작하여 아미노산 위치 107에서 종료되는 SEQ ID NO. 5에 나타낸 것과 실질적으로 동일한 아미노산 서열을 갖는 가변성 영역 및 사람 경쇄의 불변부분을 포함하는 하나의 경쇄를 포함하는 재조형 사람 항체 또는 이의 유도체.
- 제2항에 있어서, a)아미노산 위치 1에서 출발하고 아미노산 위치 123에서 종료되는, SEQ ID NO. 13에 나타낸 것과 실질적으로 동일한 아미노산 서열을 갖는 가변성 영역 및 사람 중쇄의 불변부분을 포함하는 하나의 중쇄 및 b)아미노산 위치 1에서 시작하고 아미노산 위치 107에서 종료되는, SEQ ID NO. 5에 나타낸 것과 실질적으로 동일한 아미노산 서열을 갖는 가변성 영역 및 사람 경쇄의 불변부분을 포함하는 하나의 경쇄를 포함하는 재조형 사람 항체 또는 이의 유도체.
- 제1항 내지 제5항 중 어느 한 항에 있어서, 중쇄가 중쇄 사람 불변영역 r1을 포함하는 재조형 사람 항체 및 이의 유도체.
- 제3항 내지 제5항 중 어느 한 항에 있어서, 중쇄가 중쇄 사람 불변영역 r1을 포함하고, 경쇄가 경쇄 사람 불변영역 k을 포함하는 재조형 사람 항체 및 이의 유도체.
- 제5항에 있어서, 세포주 EH31.8에 의해 생성된 H3L1로 명명되는 재조형 사람 항체 또는 이의 유도체.
- 제4항에 있어서, 세포주 EH11.13에 의해 생성된 H1L1로 명명되는 재조형 사람 항체 또는 이의 유도체.
- 제1항에 있어서, 재조형 사람 항체의 유도체.
- 본 발명의 단백질을 생성하는 적절한 숙주를 배양하고, 필요에 따라, 이 단백질을 분리하여 임의로 이를 이의 유도체로 전환시킴을 포함하여, 제1항에 따른 재조형 사람 항체, 이의 직접 등가물 또는 유도체를 재조하는 방법.
- a)FR과 CDR1H, CDR2H및 CDR3H의 순서이고, 아미노산 서열이 제3항의 정의와 같은 CDR을 교대로 포함하는 가변영역을 암호화하는 제1파트 및 임의로 b)사람 중쇄 불변부분 또는 이의 단편을 암호화하는 제2파트를 포함하는 중쇄 또는 이의 단편을 암호화하는 DNA 작제물.
- a)FR과 CDR1L, CDR2L및 CDR3L의 순서이고, 아미노산 서열이 제3항의 정의와 같은 CDR을 교대로 포함하는 가변영역을 암호화하는 제1파트 및 임의로 b)사람 중쇄 불변부분 또는 이의 단편을 암호화하는 제2파트를 포함하는 중쇄 또는 이의 단편을 암호화하는 DNA 작제물.
- 제12항에 따른 DNA 작제물 및/또는 제13항에 따른 DNA 작제물을 포함하는 하이브리드 벡터.
- 제14항에 따른 하이브리드 벡터로 형질전환시킨 숙주 세포.
- 제15항에 있어서, 세포주 EH11.13인 숙주세포.
- 제15항에 있어서, 세포주 EH31.8인 숙주세포.
- 사람에서 알레르기 반응의 예방 및/또는 치료에 사용하기 위한 제1항에 따른 재조형 사람 항체, 이의 직접 등가물 및/또는 이의 유도체.
- 제1항에 따른 항체, 직접 등가물 및/또는 이의 유도체 및 약제학적으로 허용되는 담체를 포함하는 약제학적 조성물.
- IgE의 정량적 또는 정성적 측정을 위한, 제1항에 따른 항체, 직접 등가물 및/또는 이의 유도체 용도.
- 제1항에 따른 항체, 직접 등가물 및/또는 이의 유도체를 포함하는 IgE의 정량적 또는 정성적 측정을 위한 시험 키트.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9220228.2 | 1992-09-24 | ||
| GB929220228A GB9220228D0 (en) | 1992-09-24 | 1992-09-24 | Reshaped monoclonal antibodies against an immunologlobulin isotype |
| US9220228.2 | 1992-09-24 | ||
| US95280292A | 1992-09-25 | 1992-09-25 | |
| US7/952,802 | 1992-09-25 | ||
| US07/952,802 | 1992-09-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR940006602A true KR940006602A (ko) | 1994-04-25 |
| KR100298608B1 KR100298608B1 (ko) | 2001-11-22 |
Family
ID=26301683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019930019631A KR100298608B1 (ko) | 1992-09-24 | 1993-09-24 | 면역글로불린이소타입에대한재구성된모노클로날항체 |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP1452542A3 (ko) |
| JP (2) | JP3636737B2 (ko) |
| KR (1) | KR100298608B1 (ko) |
| CN (2) | CN1078250C (ko) |
| AT (1) | ATE264388T1 (ko) |
| AU (1) | AU675449B2 (ko) |
| CA (1) | CA2106719C (ko) |
| CY (1) | CY2583B2 (ko) |
| DE (1) | DE69333484T2 (ko) |
| DK (1) | DK0589840T3 (ko) |
| ES (1) | ES2219640T3 (ko) |
| FI (2) | FI114550B (ko) |
| HK (1) | HK1056182A1 (ko) |
| IL (2) | IL107049A (ko) |
| MX (1) | MX9305920A (ko) |
| NO (1) | NO318210B1 (ko) |
| NZ (1) | NZ248743A (ko) |
| PT (1) | PT589840E (ko) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| ZA966075B (en) * | 1995-07-27 | 1998-01-19 | Genentech Inc | Protein formulation. |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| WO1997010004A1 (en) * | 1995-09-13 | 1997-03-20 | Genentech, Inc. | Methods for treatment of interstitial cystitis |
| US6127524A (en) * | 1996-10-18 | 2000-10-03 | Dade Behring Inc. | Binding molecules and computer-based methods of increasing the binding affinity thereof |
| EP1056471A4 (en) * | 1998-01-29 | 2001-05-30 | Tanox Inc | TREATMENT OF ATOPIC DERMATITIS USING IgE ANTAGONISTS |
| JP2006524036A (ja) | 2002-11-08 | 2006-10-26 | アブリンクス エン．ヴェー． | 腫瘍壊死因子αを標的とする単一ドメイン抗体およびその使用 |
| AU2003286002B2 (en) * | 2002-11-08 | 2011-06-16 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| US20060034845A1 (en) | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| US7531169B2 (en) * | 2003-02-01 | 2009-05-12 | Tanox, Inc. | High affinity anti-human IgE antibodies |
| CN102702359A (zh) * | 2004-02-02 | 2012-10-03 | 泰勒公司 | 新的IgE表位的鉴别 |
| CN105646643A (zh) | 2008-10-29 | 2016-06-08 | 阿布林克斯公司 | 单域抗原结合性分子的纯化方法 |
| BRPI0919979A2 (pt) | 2008-10-29 | 2015-12-15 | Wyeth Llc | formulações de moléculas de ligação de antígeno de domínio único |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2724625B2 (ja) * | 1987-12-31 | 1998-03-09 | タノックス・バイオシステムズ・インコーポレーテッド | ＩｇＥ産出性Ｂリンパ球上の独特な抗原決定基 |
| US5104604A (en) * | 1989-10-05 | 1992-04-14 | Dexter Electronic Materials Div. Of Dexter Corp. | Flame retardant epoxy molding compound, method and encapsulated device method of encapsulating a semiconductor device with a flame retardant epoxy molding compound |
| JP2988635B2 (ja) * | 1990-09-18 | 1999-12-13 | 塩野義製薬株式会社 | ヒトＩｇＥに対するモノクローナル抗体 |
| WO1992017207A1 (en) * | 1991-03-26 | 1992-10-15 | Tanox Biosystems, Inc. | MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IgE, BUT NOT TO IgE ON BASOPHILS |
| CA2113813C (en) * | 1991-08-14 | 2005-04-12 | Paula M. Jardieu | Immunoglobulin variants for specific fc epsilon receptors |
-
1993
- 1993-09-15 PT PT93810653T patent/PT589840E/pt unknown
- 1993-09-15 DK DK93810653T patent/DK0589840T3/da active
- 1993-09-15 DE DE69333484T patent/DE69333484T2/de not_active Expired - Lifetime
- 1993-09-15 ES ES93810653T patent/ES2219640T3/es not_active Expired - Lifetime
- 1993-09-15 AT AT93810653T patent/ATE264388T1/de not_active IP Right Cessation
- 1993-09-15 EP EP04008222A patent/EP1452542A3/en not_active Withdrawn
- 1993-09-15 EP EP93810653A patent/EP0589840B1/en not_active Expired - Lifetime
- 1993-09-20 IL IL107049A patent/IL107049A/en not_active IP Right Cessation
- 1993-09-20 AU AU47488/93A patent/AU675449B2/en not_active Ceased
- 1993-09-20 IL IL173988A patent/IL173988A0/en unknown
- 1993-09-22 CA CA002106719A patent/CA2106719C/en not_active Expired - Fee Related
- 1993-09-22 NZ NZ248743A patent/NZ248743A/en not_active IP Right Cessation
- 1993-09-22 FI FI934145A patent/FI114550B/fi active IP Right Grant
- 1993-09-23 NO NO19933394A patent/NO318210B1/no not_active IP Right Cessation
- 1993-09-24 KR KR1019930019631A patent/KR100298608B1/ko not_active IP Right Cessation
- 1993-09-24 MX MX9305920A patent/MX9305920A/es not_active IP Right Cessation
- 1993-09-24 JP JP23818093A patent/JP3636737B2/ja not_active Expired - Fee Related
- 1993-09-24 CN CN93119845A patent/CN1078250C/zh not_active Expired - Fee Related
-
2001
- 2001-12-14 CN CNB011436433A patent/CN1254487C/zh not_active Expired - Fee Related
-
2003
- 2003-11-21 HK HK03108492A patent/HK1056182A1/xx not_active IP Right Cessation
-
2004
- 2004-05-19 FI FI20040696A patent/FI115838B/fi active IP Right Grant
- 2004-07-07 JP JP2004201096A patent/JP3718214B2/ja not_active Expired - Fee Related
-
2005
- 2005-09-08 CY CY0500048A patent/CY2583B2/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002368077B2 (en) | Super humanized antibodies | |
| US6342587B1 (en) | A33 antigen specific immunoglobulin products and uses thereof | |
| US5869620A (en) | Multivalent antigen-binding proteins | |
| DE69330523T2 (de) | Immunoglobuline ohne leichte ketten | |
| KR940006602A (ko) | 면역글로불린 이소타입에 대한 재조형 모노클로날 항체 | |
| KR960706560A (ko) | 인화 항체 및 이것의 사용 방법(humanized antibodies and uses thereof) | |
| RU94045249A (ru) | Мономерное антитело, способ получения антитела, димерный слитый белок, способ получения белка, набор конструкций | |
| HUP9802401A2 (hu) | Az emberi gp39-protein különböző epitópjaira specifikus monoklonális antitestek, valamint eljárások az ilyen antitestek diagnosztikai és terápiás alkalmazására | |
| RU2004121673A (ru) | Человеческие полипептиды, вызывающие или опосредующие лизис клеток, включая клетки лимфоидных опухолей | |
| WO2003060080A3 (en) | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them | |
| RU2003100512A (ru) | Антитела к человеческому мср-1 | |
| BR0207151A (pt) | Moléculas de aglutinação terapêuticas | |
| US6346249B1 (en) | Methods for reducing the effects of cancers that express A33 antigen using A33 antigen specific immunoglobulin products | |
| EP0584421A1 (en) | Immunoglobulins devoid of light chains | |
| KR900013986A (ko) | 종양-관련항원에 대한 모노클로날 항체(MAb_s), 이의 제조방법 및 용도 | |
| Robbins et al. | Serologic and molecular characterization of a human monoclonal rheumatoid factor derived from rheumatoid synovial cells | |
| US20190031770A1 (en) | Intercalated single-chain variable fragments | |
| Terness et al. | The natural human IgG anti-F (ab') 2 antibody recognizes a conformational IgG1 hinge epitope. | |
| Vidal et al. | Alternative mechanism of protein A-immunoglobulin interaction the VH-associated reactivity of a monoclonal human IgM. | |
| US9273138B2 (en) | Humanized forms of monoclonal antibodies to human GnRH receptor | |
| Al Qaraghuli et al. | Defining the complementarities between antibodies and haptens to refine our understanding and aid the prediction of a successful binding interaction | |
| Park et al. | Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens | |
| RU2005121669A (ru) | Анти-nogo антитела ("11с7") и их фармацевтическое использование | |
| CN118388643B (zh) | 结合冠状病毒SARS-CoV-2和SARS-CoV刺突蛋白RBD的中和抗体ZJ-9及其应用 | |
| CN118359710B (zh) | 结合冠状病毒SARS-CoV-2和SARS-CoV刺突蛋白RBD的中和抗体ZJ-2及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19930924 |
|
| PG1501 | Laying open of application | ||
| N231 | Notification of change of applicant | ||
| PN2301 | Change of applicant |
Patent event date: 19970731 Comment text: Notification of Change of Applicant Patent event code: PN23011R01D |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19980924 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19930924 Comment text: Patent Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20000616 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20010302 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20010601 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20010602 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20040507 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20050511 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20060515 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20070523 Start annual number: 7 End annual number: 7 |
|
| PR1001 | Payment of annual fee |
Payment date: 20080522 Start annual number: 8 End annual number: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20090525 Year of fee payment: 9 |
|
| PR1001 | Payment of annual fee |
Payment date: 20090525 Start annual number: 9 End annual number: 9 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
Termination category: Default of registration fee Termination date: 20110509 |